SCHEMBL4044583

SCHEMBL4044583

COc1ccc2c(c1)NC(c1ccc(Cl)nc1)(C(C(=O)NC1CCCCC1)C1CCCCC1)N2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.42
HPGDS O60760 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP1A2 P05177 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
CNR1 P21554 1/20 0.38
TSHR P16473 1/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
MAPT P10636 1/20 0.37
ALDH1A1 P00352 2/20 0.37
EPHX2 P34913 2/20 0.37
EPHX1 P07099 1/20 0.37
CYP2D6 P10635 1/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4038480 0.89 NR1H4 (0.48) NR1H4SMN1; SMN2MEN1KMT2ACYP3A4
SCHEMBL4037444 0.89 NR1H4 (0.48) NR1H4SMN1; SMN2MEN1KMT2ACYP3A4
SCHEMBL4045000 0.89 NR1H4 (0.48) NR1H4SMN1; SMN2MEN1KMT2ACYP3A4
SCHEMBL4040321 0.88 HPGDS (0.40) NR1H4HPGDSSMN1; SMN2MEN1KMT2A
SCHEMBL4035053 0.87 LMNA (0.44) NR1H4SMN1; SMN2MEN1KMT2ACYP3A4
SCHEMBL4041511 0.87 LMNA (0.44) NR1H4SMN1; SMN2MEN1KMT2ACYP3A4
SCHEMBL4038748 0.87 LMNA (0.44) NR1H4SMN1; SMN2MEN1KMT2ACYP3A4
SCHEMBL4044980 0.86 LMNA (0.43) NR1H4SMN1; SMN2MEN1KMT2ACYP3A4
SCHEMBL4039159 0.86 LMNA (0.42) NR1H4SMN1; SMN2MEN1KMT2ACYP3A4
SCHEMBL4042532 0.86 NPC1 (0.42) SMN1; SMN2MEN1KMT2ACYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP claimed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO claimed
EP-3043865-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2016-07-20 EP disclosed
WO-2015036442-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2015-03-19 WO disclosed
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP disclosed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed